Atara Biotherapeutics
ATRA
139 hedge funds and large institutions have $316M invested in Atara Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 49 increasing their positions, 53 reducing their positions, and 24 closing their positions.
19,642% more call options, than puts
Call options by funds: $5.13M | Put options by funds: $26K
0.12% less ownership
Funds ownership: 4.22% → 4.1% (-0.12%)
8% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 53
10% less funds holding
Funds holding: 154 → 139 (-15)
16% less capital invested
Capital invested by funds: $376M → $316M (-$59.9M)
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$6.19M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.69M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.39M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$3.14M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$6.52M |
| 2 |
6CM
683 Capital Management
New York
|
-$4.91M |
| 3 |
JP Morgan Chase
New York
|
-$3.27M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.73M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.06M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$149K | -1,572 | Closed |
|
|
DTL
152
Dynamic Technology Lab
Singapore
| – | -$129K | -1,361 | Closed |
|
153
Point72 Asset Management
Stamford,
Connecticut
| – | -$113K | -1,200 | Closed |
|
|
SSA
154
Schonfeld Strategic Advisors
New York
| – | -$109K | -1,154 | Closed |
|
155
Handelsbanken Fonder
Stockholm,
Sweden
| – | -$72K | -764 | Closed |
|
|
CC
156
Cipher Capital
New York
| – | -$49K | -518 | Closed |
|
|
DT
157
Diversified Trust
Memphis,
Tennessee
| – | -$48K | -510 | Closed |
|
|
PCM
158
Princeton Capital Management
Red Bank,
New Jersey
| – | -$43K | -450 | Closed |
|
159
HighTower Advisors
Chicago,
Illinois
| – | -$42K | -424 | Closed |
|
|
JMPWA
160
JP Morgan Private Wealth Advisors
San Francisco,
California
| – | -$38K | -400 | Closed |
|
|
PHK
161
Point72 Hong Kong
Hong Kong
| – | -$24K | -257 | Closed |
|
162
Group One Trading
Chicago,
Illinois
| – | -$23.2K | -223 | Closed |
|
ATRA Hedge Fund Activity: Q4 2022 in Review
139 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2022, worth a combined $316M — down 16% from $376M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ATRA and 13 opened new positions — a net loss of 11 holders — while 53 trimmed existing stakes and 49 added.
The largest buyer was Goldman Sachs, adding an estimated $6.19M. The largest seller was Maverick Capital, cutting an estimated $6.52M.
- 139 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2022, down from 154 in Q3 2022.
- Funds reported $316M of Atara Biotherapeutics stock for Q4 2022, down 16% quarter-over-quarter.
- 13 funds opened new Atara Biotherapeutics positions in Q4 2022 and 24 closed out, a net change of -11 holders.
- The largest Atara Biotherapeutics buyer in Q4 2022 was Goldman Sachs, an estimated $6.19M added.
- The largest Atara Biotherapeutics seller in Q4 2022 was Maverick Capital, an estimated $6.52M sold.
Based on aggregated 13F filings for Q4 2022.